SPECIAL COMMENTARIES: Edited by Narla MohandasChallenges and opportunities in shared care for international patients treated with cellular therapy for nonmalignant diseaseMina, Syeda A.a; Muhsen, Ibrahim N.b; Hashmi, Shahrukh K.c,d,e Author Information aDepartment of Medicine, Mayo Clinic, Phoenix/Scottsdale, Arizona bSection of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas cDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA dDepartment of Medicine, Sheikh Shakbout Medical City eMedical Affairs, Khalifa University, Abu Dhabi, United Arab Emirates Correspondence to Shahrukh K. Hashmi, MD, MPH, Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA. Tel: +1 507 538 3270; fax: +1 507 284 4011; e-mail: [email protected] Current Opinion in Hematology 30(1):p 22-27, January 2023. | DOI: 10.1097/MOH.0000000000000742 Buy Metrics Abstract As cellular therapies gradually become the mainstay of treatment for several nonmalignant diseases, there appears to be varied accessibility to these therapies globally. Despite considerable burden of nonmalignant conditions, such as sickle cell disease, thalassemia, and aplastic anemia in populations of low–middle-income countries, the utilization of cellular therapies remain sparse because of lack of resources. Globally, the frequency of hematopoietic stem cell transplant (HSCT) has increased disproportionately in countries with higher gross national income (GNI) per capita, governmental healthcare expenditures, and a high human development index. This leads to a large subset of international patients seeking care in the United States. This review summarizes the unique set of challenges that often arise when offering sophisticated therapies such as HSCT to international patients constituting of cross-cultural, logistical, financial, and medical challenges and the opportunities that are available to bridge the gap. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.